The Latest Cardiac and Vascular News
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) — CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s long-term growth plan. Jared Oasheim, who joined CVRx in 2015, was promoted from Vice President of Finance to Chief Financial Officer (CFO). He […]
WINNIPEG, MB, Nov. 18, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. (“Nexus”) in the U.S. District Court for the Northern District of Illinois, which […]
Geist brings operational experience to Quanterix as the company scales to support rapid growth and commercial success BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has named William Geist to the position of chief operating officer (COO), […]
ENGLEWOOD, Colo., Nov. 19, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced it has been ranked 13th in revenue growth among all medical device companies in the U.S. and Canada on Deloitte’s […]
– In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular disease – Recurrent cardiovascular events in people with type 2 diabetes are […]
VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu Ying Ngan Ng, Chi Wing Ngan […]
The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer BASKING RIDGE, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, […]
– RAPID and completed NODE-301 studies could potentially fulfill efficacy requirement for future NDA for etripamil in patients with PSVT – – RAPID investigates efficacy of second dose of etripamil for patients with persistent PSVT – – RAPID results expected late 2021/early 2022 – MONTREAL and CHARLOTTE, N.C., Nov. 18, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical […]
– In new results published in The Lancet Diabetes & Endocrinology, Jardiance reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular disease – Recurrent cardiovascular events in people with […]
Large randomized, sham-controlled trial evaluates interatrial shunting in a heart failure population currently without effective treatment TEWKSBURY, Mass., Nov. 17, 2020 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The trial […]
